Vivoryon's VIVA-MIND trial echoed the disappointing Alzheimer’s findings of its VIVIAD trial but offers promise in treating ...

Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving ...

Vivoryon Therapeutics announces Phase II trial results for varoglutamstat, showing no efficacy in cognitive endpoints but ...

Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development, University of Florida, Gainesville, Florida 31610, United States ...

MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat’s benefit on eGFR in VIVIAD; Company now has two independent doub ...

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) have received a consensus recommendation of ...

After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...

Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide ...

Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 ...

A: Animal; ACE: Accessory cholera enterotoxin; H: Human; ZOT: Zonula occludens toxin.

Public Sector Pension Investment Board cut its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 3.1% ...